Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats

Metabolism: Clinical and Experimental

Volumn 62, Issue 11, 2013, Pages 1641-1650

  Merroun, Ikram ^a   Sánchez González, Cristina ^a   Martínez, Rosario ^a   López Chaves, Carlos ^a   Porres, Jesús M ^a   Aranda, Pilar ^a   Llopis, Juan ^a   Galisteo, Milagros ^a   Zarzuelo, Antonio ^a   Errami, Mohammed ^b   López Jurado, María ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b ABDELMALEK ESSAADI UNIVERSITY   (Morocco)

Author keywords

Biochemical parameters; CB1 receptor inverse agonist; Liver status; Oxygen consumption; Zucker rats

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CANNABINOID 1 RECEPTOR ANTAGONIST; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENERGY EXPENDITURE; FAT CONTENT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID METABOLISM; LIVER WEIGHT; MALE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; STEATOSIS; WEIGHT GAIN; ZUCKER RAT;

ALANINE TRANSMINASE; ALT; AM 251; ASPARTATE TRANSAMINASE; AST; BIOCHEMICAL PARAMETERS; CB(1) RECEPTOR INVERSE AGONIST; DIMETHYL SULFOXIDE; DMSO; LIVER STATUS; OXYGEN CONSUMPTION; ZUCKER RATS;

ANIMALS; BIOLOGICAL MARKERS; CANNABINOID RECEPTOR ANTAGONISTS; EATING; ENERGY METABOLISM; FATTY LIVER; INSULIN; INSULIN RESISTANCE; LEPTIN; LIPID METABOLISM; LIVER; MALE; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; WEIGHT GAIN;

EID: 84886406461     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.06.011     Document Type: Article

References (48)

1. C.L. Ogden, S.Z. Yanovski, M.D. Carroll, and K.M. Flegal The epidemiology of obesity Gastroenterology 132 2007 2087 2102 (Pubitemid 46693751)
2. V. Di Marzo, and I. Matías Endocannabinoid control of food intake and energy balance Nat Med 8 2005 585 589 (Pubitemid 40594198)
3. G. Kunos Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 120 2007 S18 S24
4. 1 receptors Psychopharmacology 143 1999 315 317 (Pubitemid 29204987)
5. B. Kola, E. Hubina, S.A. Tucci, T.C. Kirkham, E.A. Garcia, and S.E. Mitchell Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase J Biol Chem 280 2005 25196 25201 (Pubitemid 40934612)
6. C. Ravinet-Trilloi, C. Delgorge, C. Menet, M. Arnone, and P. Soubrie CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity Int J Obes Relat Metab Disord 46 2004 640 648 (Pubitemid 38491158)
7. Z. Thornton-Jones, S.P. Vickers, and P.G. Clifton The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food Psychopharmacology 179 2005 452 460 (Pubitemid 40569048)
8. J.P. Després, R. Ross, G. Boka, N. Almeras, and I. Lemieux ADAGIO-lipids investigators. Effect of rimonabant on the high-triglyceride/low- HDL-Cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-lipids trial Arterioscler Thromb Vasc Biol 29 2009 416 423
9. A. Serrano, I. Del Arco, F. Javier Pavón, M. Macías, V. Perez-Valero, and F. Rodríguez de Fonseca The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats Neuropharmacology 54 2008 226 234
10. G. Colombo, R. Agabio, G. Diaz, C. Lobina, R. Reali, and G.L. Gessa Appetite suppression and weight loss after the cannabinoid antagonist SR 141716 Life Sci 63 1998 113 117 (Pubitemid 28378339)
11. E.T. Wargent, M.S. Zaibi, C. Silvestri, D.C. Hislop, C.J. Stocker, and C.G. Stott The cannabinoid Δ(9)-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity Nutr Diabetes 27 3 2013 e68
12. V. Di Marzo, S.K. Goparaju, L. Wang, J. Liu, S. Batkai, Z. Jarai, and F. Fezza Leptin-regulated endocannabinoids are involved in maintaining food intake Nature 410 2001 822 825 (Pubitemid 32303781)
13. C. Pagano, C. Pilon, A. Calcagon, R. Urbanet, M. Rossato, and G. Milan The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium dependent mechanisms J Clin Endocrinol Metab 92 2007 4810 4819 (Pubitemid 350223464)
14. D. Osei-Hyiaman, M. DePetrillo, P. Pacher, J. Liu, S. Radaeva, and S. Bátkai Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity J Clin Invest 115 2005 1298 1305 (Pubitemid 40629049)
15. I. Matias, A.V. Vergoni, S. Petrosino, A. Ottani, A. Pocai, and A. Bertolini Regulation of hypothalamic endocannabinoid levels by neuropeptide and hormones involved in food intake and metabolism: insulin and melanocortins Neuropharmacology 54 2008 206 212 (Pubitemid 350299405)
16. M. Bordicchia, I. Battistoni, L. Mancinelli, E. Giannini, G. Refi, and D. Minardi Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans Metabolism 59 2010 734 741
17. G.M. Leinninger, Y.H. Jo, and R.L. Leshan Leptin acts via leptin receptor-expressing lateral hypothalamic neurons to modulate the mesolimbic dopamine system and suppress feeding Cell Metab 10 2009 89 98
18. P.K. Thanos, R.C. Ramalhete, M. Michaelides, Y.K. Piyis, G.J. Wang, and N.D. Volkow Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions Synapse 62 2008 637 664
19. European Union Council Directional on the protection of animals used for scientific purposes Off J Eur Union 2010 L276/33-79
20. D. Cota, G. Marsicano, M. Tschop, Y. Grubler, C. Flachskamm, and M. Schubert The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest 112 2003 423 431 (Pubitemid 38063771)
21. O. Jbilo, C. Ravinet-Trillou, M. Amone, I. Buisson, E. Bribes, and A. Peleraux The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance FASEB 19 2005 1567 1569 (Pubitemid 41279033)
22. J.R. Hadcock, D.A. Griffith, P.A. Iredale, P.A. Carpino, R.L. Dow, and S.C. Black In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB1 receptor antagonist for the management of obesity Biochem Biophy Res Comm 394 2010 366 371
23. 1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats Psychopharmacol 167 2003 103 111 (Pubitemid 36535298)
24. Y.L. Liu, I.P. Connolet, and C.A. Wilson Effects of the cannabinoid CB1 receptor antagonist SR 141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob) mice Int J Obes 29 2 2005 183 187 (Pubitemid 40188413)
25. A.M. Strack, S. Susan Nicolich, T. Faidley, J. Achanfuo-Yeboah, and P.K. Cunningham Cannabinoid-1 receptor inhibition prevents the reduction of 24-hour energy expenditure with weight loss Metab Clin Exp 61 4 2012 546 553
26. A.W. Herling, S. Kilp, R. Elvert, G. Haschke, and W. Kramer Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats Endocrinology 149 5 2008 2557 2566 (Pubitemid 351574492)
27. N. Perwitz, M. Fasshauer, and J. Klein Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin Horm Metab Res 38 2006 356 358 (Pubitemid 43864960)
28. J. Fruebis, T.S. Tsao, S. Javorschi, D. Ebbets-Reed, M.R.S. Erickson, and F.T. Yen Proteolytic cleavage product of 30-KDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice Proct Natl Acad Sci USA 98 2001 2005 2010 (Pubitemid 32165613)
29. M. Gary-Bobo, G. Elachouri, J.F. Gallas, P. Janiak, P. Marini, and C. Ravinet-Trillou Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats Hepatology 46 2007 122 129 (Pubitemid 47171928)
30. D. Cota, D.A. Sandoval, M. Olivieri, E. Prodi, D.A. D'Alessio, and S.C. Woods Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism Obesity 17 8 2009 1641 1645
31. B. Poirier, J.P. Bidouard, C. Cadrouvele, X. Marniquet, B. Staels, and S.E. O'Connor The anti-obesity effect of rimonabant is associated with an improved serum lipid profile Diabetes Obes Metab 7 2005 65 72
32. C.M. de Souza Batista, R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, and J. Pray Omentin plasma levels and gene expression are decreased in obesity Diabetes 56 6 2007 1655 1661 (Pubitemid 46842600)
33. I. Matias, M. Gonthier, P. Orlando, V. Martiadis, L. De Petrocellis, and C. Cervino Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia J Clin Endocrinol Metab 91 2006 3171 3180 (Pubitemid 44271774)
34. R. Sarzani, M. Bordicchia, P. Marcucci, S. Bedetta, S. Santini, and A. Giovagnoli Altered pattern of cannabinoid type 1 receptor expression in adipose tissue of dysmetabolic and overweight patients Metabolism 58 2009 361 367
35. D. Osei-hyiaman, J. Liu, L. Zhou, G. Godlewski, J. Harvey-White, and W.I. Jeong Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice J Clin Invest 118 2008 3160 3169
36. N. Irwin, K. Hunter, N. Frizzell, and P.R. Flatt Antidiabetic effects of subchronic administration of the cannabinoid receptor (CB1) antagonist, AM 251, in obese diabetic (ob/ob) mice Eur J Pharmacol 581 2008 226 233
37. A. De Gottardi, L. Spahr, F. Ravier-Dall'Antonia, and A. Hadengue Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes Liver Int 30 10 2010 1482 1489
38. K.M. Starowicz, L. Cristino, I. Matias, R. Capasso, A. Racioppi, and A.A. Izzo Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet Obesity 16 2008 553 565 (Pubitemid 351328005)
39. M. Nakata, and T. Yada Cannabinoids inhibit insulin secretion and cytosolic Ca2 + oscillation in islet beta-cells via CB1 receptors Regul Pep 145 2008 49 53 (Pubitemid 350296356)
40. A. Scheen, N. Finer, P. Hollander, M.D. Jensen, and L.F. Van Gaal Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study Lancet 368 2006 1660 1672 (Pubitemid 46048528)
41. C. Li, P.M. Jones, and S.J. Persaud Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas Pharmacol Ther 129 2011 307 320
42. J.P. Després, A. Golay, and L. Sjostrom Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 353 2005 2121 2134 (Pubitemid 41653104)
43. A.E. Rigamonti, A. Sartorio, S.M. Bonomo, M. Giunta, G. Grassi, and M. Perotti Effect of a somatostatin infusion on circulating levels of adipokines in obese women Metabolism 61 2012 1797 1802
44. M. Krause, J. Rodrigues-Krause, C. O'Hagan, G. De Vito, C. Boreham, and D. Susta Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study Metabolism 61 2012 1528 1537
45. I. Matias, and V. Di Marzo Endocannabinoids and the control of energy balance Trends Endocrinol Metab 18 2007 27 37 (Pubitemid 44960014)
46. V. Di Marzo The endocannabinoid system in obesity and type 2 diabetes Diabetologia 51 2008 1356 1367
47. L. Vong, C. Ye, Z. Yang, B. Choi1, S. Chua, and B.B. Lowell Leptin action on GABAergic neurons prevents obesity and reduces inhibitory tone to POMC neurons Neuron 71 2011 142 154
48. A receptors Br J Pharmacol 165 2012 2479 2484